首页> 外文期刊>Bone marrow transplantation >Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
【24h】

Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.

机译:造血干细胞移植后儿童的肝静脉闭塞性疾病:发生率,危险因素和结局。

获取原文
获取原文并翻译 | 示例
       

摘要

Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P=0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P=0.012), number of previous HSCT (P=0.014), and pretransplant serum ferritin (P=0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6+/-2842.5 ng/ml) than in HSCT without VOD (1315.9+/-1094.4 ng/ml) (P<0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.
机译:2005年1月至2007年12月,在韩国四个儿科HSCT中心对374名儿童进行了467例造血干细胞移植(HSCT)(217例自体造血和250例同种异体HSCT)。在467例移植物中,静脉闭塞性疾病(VOD) )在HSCT后的中位数为10天的72个移植中(15.4%)发育。多变量分析显示,含BU或TBI的方案(P = 0.002),无脂前列腺素E1的VOD预防(PGE1)(P = 0.012),既往HSCT数量(P = 0.014)和移植前血清铁蛋白(P = 0.018) )是发展VOD的独立危险因素。具有VOD的HSCT中的平均血清铁蛋白水平(2109.6 +/- 2842.5 ng / ml)明显高于没有VOD的HSCT(1315.9 +/- 1094.4 ng / ml)(P <0.001)。带VOD的移植与不带VOD的移植相比,HSCT在100天内死亡的相对风险为3.39(置信区间:1.78-6.45)。我们的结果表明,lipo-PGE1可能对VOD的发展具有保护作用,而移植前血清铁蛋白可能是VOD的危险因素。需要进行更大的前瞻性研究,以确认脂质-PGE1和铁螯合疗法在降低VOD发生率方面的可能作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号